Status:
UNKNOWN
Zürich Pulmonary Hypertension Outcome Assessment Cohort
Lead Sponsor:
University of Zurich
Conditions:
Pulmonary Hypertension Outcome Assessment
Eligibility:
All Genders
18-90 years
Brief Summary
PH is a serious disease with a dismal prognosis and impaired quality of life when left untreated. Reliable patient centered and prognostically relevant outcome measures are highly warranted in the fie...
Detailed Description
PH is a serious disease with a dismal prognosis and impaired quality of life when left untreated. Advances in medical therapy have improved survival according to recent registries, but are associated ...
Eligibility Criteria
Inclusion
- Patients with precapillary pulmonary hypertension
- Adult male and female patients of all ages referred to our center for evaluation/treatment of PH
- Written informed consent by the subject after information about the research project
Exclusion
- Patients with severe concomitant left heart disease (left ventricular ejection fraction \<40%).
- Patients with restrictive lung disease (FVC\<60% predicted); obstructive lung disease (forced expiratory volume (FEV) \<60% predicted, with FEV 1/FVC\<70%).
- Patients with any other disease limiting their ability to move (skeletal disease, neurological disease, etc.)
Key Trial Info
Start Date :
September 1 2014
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2024
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT02249806
Start Date
September 1 2014
End Date
September 1 2024
Last Update
November 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University Hospital Zürich
Zurich, Switzerland, 8091